FDA grants Breakthrough Therapy Designation for Roche's Gazyva (obinutuzumab) in Lupus Nephritis - GlobeNewswire
FDA grants Breakthrough Therapy Designation for Roche's Gazyva (obinutuzumab) in Lupus Nephritis GlobeNewswire
There are currently no U.S. FDA-approved medicines for lupus nephritis; The designation is based on the results of the phase II NOBILITY study that showed ...
Comments
Post a Comment